AZO vs CVNA

The Advanced Deterministic Scorecard shows a weak Piotroski F-Score of 4/9, indicating marginal financial health, and the absence of an Altman Z-Score limits distress risk assessment. Despite solid profitability metrics like a 16.94% operating margin and 52.15% gross margin, recent earnings declines and negative earnings surprises over the last four quarters raise concerns. Valuation appears stretched relative to peers with a P/E of 25.77, though below sector average, while insider selling and weakening EPS growth temper bullish sentiment. The stock trades significantly above its intrinsic value estimate of $1,004.92, suggesting substantial premium pricing based on growth expectations.

CVNA presents a stark dichotomy between explosive growth and fragile fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company has achieved massive earnings growth (946.7% YoY) and strong liquidity (Current Ratio 4.31), it trades at a severe premium to its Graham Number ($67.9) and Intrinsic Value ($249.87). The current price of $409.08 reflects high growth expectations that are not yet supported by deterministic health metrics or insider conviction. Consequently, the stock is a high-momentum play with significant underlying fundamental risk.